Skip to main content

Anti-VEGF therapies in the clinic.

Publication ,  Journal Article
Meadows, KL; Hurwitz, HI
Published in: Cold Spring Harbor perspectives in medicine
October 1, 2012

The development and use of antiangiogenesis agents, particularly those targeting vascular endothelial growth factor (VEGF), has become an integral component of anticancer regimens for many tumor types. This review is intended to highlight some of the most important clinical successes and failures of anti-VEGF therapies, and where possible, to suggest important lessons that have been learned. This review emphasizes data from agents that have been FDA approved and/or have completed phase III studies.

Duke Scholars

Published In

Cold Spring Harbor perspectives in medicine

EISSN

2157-1422

Publication Date

October 1, 2012

Volume

2

Issue

10

Related Subject Headings

  • 1116 Medical Physiology
  • 1108 Medical Microbiology
  • 1101 Medical Biochemistry and Metabolomics
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Meadows, K. L., & Hurwitz, H. I. (2012). Anti-VEGF therapies in the clinic. Cold Spring Harbor Perspectives in Medicine, 2(10).
Meadows, K. L., and H. I. Hurwitz. “Anti-VEGF therapies in the clinic.Cold Spring Harbor Perspectives in Medicine 2, no. 10 (October 1, 2012).
Meadows KL, Hurwitz HI. Anti-VEGF therapies in the clinic. Cold Spring Harbor perspectives in medicine. 2012 Oct 1;2(10).
Meadows, K. L., and H. I. Hurwitz. “Anti-VEGF therapies in the clinic.Cold Spring Harbor Perspectives in Medicine, vol. 2, no. 10, Oct. 2012.
Meadows KL, Hurwitz HI. Anti-VEGF therapies in the clinic. Cold Spring Harbor perspectives in medicine. 2012 Oct 1;2(10).

Published In

Cold Spring Harbor perspectives in medicine

EISSN

2157-1422

Publication Date

October 1, 2012

Volume

2

Issue

10

Related Subject Headings

  • 1116 Medical Physiology
  • 1108 Medical Microbiology
  • 1101 Medical Biochemistry and Metabolomics